The combination of CJC-1295 without DAC and Ipamorelin is one of the most widely investigated dual-peptide paradigms in neuroendocrine and metabolic research. By concurrently targeting distinct receptor pathways involved in somatotroph stimulation, this pairing allows investigators to examine synergistic growth hormone dynamics in preclinical models.
The combination of CJC-1295 without DAC and Ipamorelin is one of the most widely investigated dual-peptide paradigms in neuroendocrine and metabolic research. By concurrently targeting distinct receptor pathways involved in somatotroph stimulation, this pairing allows investigators to examine synergistic growth hormone dynamics in preclinical models.
The combination of CJC-1295 without DAC and Ipamorelin represents a dual-acting preclinical research regimen designed to evaluate synergistic growth hormone (GH) secretion. CJC-1295 without DAC serves as a GHRH receptor agonist, while Ipamorelin selectively targets the ghrelin receptor. Together, they elicit amplified, pulsatile GH release and downstream IGF-1 elevation in laboratory models.
When evaluated individually, both compounds operate through well-defined molecular mechanisms, but their co-administration allows researchers to study additive signal transduction within anterior pituitary somatotrophs. CJC-1295 without DAC (also known as Modified GRF 1-29) is a synthetic 29-amino-acid peptide derived from human growth hormone-releasing hormone (GHRH). By omitting the Drug Affinity Complex (DAC), the peptide exhibits a physiological, short half-life suited for mimicking natural, pulsatile hormone release.
In contrast, Ipamorelin is a synthetic pentapeptide that acts as a selective growth hormone secretagogue receptor (GHS-R1a) agonist. Unlike earlier generation secretagogues, Ipamorelin demonstrates exceptional selectivity, failing to induce significant secretion of ACTH, cortisol, or prolactin during preclinical evaluation. Researchers studying research peptides frequently utilize this dual pairing to inspect maximum endogenous secretagogue amplification while minimizing off-target endocrine activity.
To understand the biochemical rationale behind pairing CJC-1295 without DAC with Ipamorelin, investigators analyze the dual-receptor dynamics situated at the pituitary level. Somatotroph cells express both GHRH receptors (GHRH-R) and ghrelin/growth hormone secretagogue receptors (GHS-R1a). Activation of GHRH-R stimulates intracellular adenylate cyclase, elevating cyclic adenosine monophosphate (cAMP) and activating protein kinase A (PKA). This signaling cascade prompts the transcription and secretion of growth hormone storage granules.
Simultaneously, Ipamorelin binding to GHS-R1a initiates a distinct intracellular pathway mediated by phospholipase C (PLC), leading to the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 triggers the release of intracellular calcium from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). The convergent elevation of both cAMP-PKA and IP3-Ca2+ secondary messenger systems yields a synergistic amplification of GH exocytosis that exceeds the sum of either peptide administered in isolation.
Preclinical studies suggest that this dual-pathway activation preserves the physiological feedback architecture governed by somatostatin. Because the stimulus relies on endogenous GH production rather than exogenous hormone administration, somatotroph cells retain normal refractory reset periods, preventing complete downregulation or receptor desensitization during controlled exposure windows.
A critical distinction in secretagogue research involves the structural difference between CJC-1295 without DAC and CJC-1295 with DAC. The Drug Affinity Complex (DAC) is a maleimidopropionic acid moiety added to the lysine residue at position 30. DAC covalently binds to endogenous circulating albumin in vivo, extending the elimination half-life from approximately 30 minutes to more than 6 to 8 days.
In laboratory models where continuous, baseline elevation of GH and insulin-like growth factor 1 (IGF-1) is required, the DAC variant provides prolonged exposure. However, continuous GH elevation disrupts natural pulsatile dynamics and can lead to elevated baseline IGF-1 levels without mimicking natural physiological peaks.
Conversely, CJC-1295 without DAC provides a rapid, transient peak in plasma GHRH activity. When combined with Ipamorelin, it recreates discrete, high-amplitude biological pulses of growth hormone. This pulsatile profile is preferred in research paradigms examining normal physiological repair, metabolic regulation, and circadian-aligned secretagogue activity.
In animal models, co-administration of GHRH analogs and ghrelin mimetics yields marked elevations in circulating serum growth hormone within 15 to 30 minutes post-administration. In rodent models, researchers have observed peak GH responses up to four- to ten-fold higher than vehicle controls, depending on the dosage ratios evaluated in experimental designs.
The primary downstream mediator of growth hormone biological activity is Insulin-like Growth Factor 1 (IGF-1), synthesized predominantly in hepatic tissue in response to GH binding to hepatic growth hormone receptors. Preclinical studies indicate that sustained daily administration of CJC-1295 without DAC and Ipamorelin leads to predictable, dose-dependent increases in total serum IGF-1 levels over multi-week research intervals.
This sustained elevation in IGF-1 facilitates research into diverse physiological domains, including nitrogen retention, extracellular matrix synthesis, cellular proliferation in musculoskeletal tissues, and accelerated cellular turnover during tissue repair protocols.
A primary advantage of utilizing Ipamorelin over first- and second-generation growth hormone releasing peptides (GHRPs) is its high receptor selectivity. Early compounds such as GHRP-2 and GHRP-6 frequently demonstrate cross-reactivity with central stress pathways, inducing transient spikes in adrenocorticotropic hormone (ACTH), systemic cortisol, and prolactin.
In vitro binding assays and in vivo non-human primate models confirm that Ipamorelin binds specifically to GHS-R1a without stimulating the hypothalamic-pituitary-adrenal (HPA) axis. When paired with CJC-1295 without DAC, the overall selectivity profile remains intact. Cortisol and prolactin levels remain unchanged relative to baseline controls across standard experimental models.
This absence of stress axis stimulation is essential for isolation experiments where confounding variables—such as glucocorticoid-induced catabolism or prolactin-mediated immune modulation—could compromise data regarding tissue repair, protein synthesis, or lipid oxidation.
To select the optimal experimental tools, researchers frequently compare CJC-1295 without DAC and Ipamorelin against other secretagogues in the GHRH and GHRP classes. The table and comparative synthesis below illustrate key biochemical parameters across commonly evaluated compounds:
While Sermorelin shares the native 1-29 GHRH sequence, CJC-1295 without DAC features four amino acid substitutions (D-Ala2, Gln8, Ala15, Leu27) that enhance resistance to enzymatic cleavage by dipeptidyl peptidase IV (DPP-IV). Consequently, CJC-1295 without DAC maintains greater metabolic stability in plasma than native Sermorelin. Meanwhile, pairing CJC-1295 No DAC with Ipamorelin provides superior receptor selectivity compared to pairing GHRH analogs with non-selective agents like GHRP-2 or Hexarelin.
Lyophilized research peptides require precise handling and storage protocols to preserve bioactivity and prevent structural degradation. Upon receipt, lyophilized vials containing CJC-1295 without DAC and Ipamorelin should be stored in a controlled freezer environment at -20°C or -80°C for long-term stability.
For reconstitution, laboratory technicians should utilize bacteriostatic water (0.9% benzyl alcohol) or sterile physiological saline, depending on the requirements of the downstream assay. Reconstitution should be performed by gently directing the diluent along the glass wall of the vial, followed by gentle swirling. High-shear mechanical agitation or vortexing must be avoided, as shear forces can disrupt the tertiary structure of peptide chains.
Following reconstitution, liquid aliquots should be stored at 2°C to 8°C and evaluated within a 14- to 28-day window to minimize potential hydrolysis or oxidation. For detailed protocols on preparing reagents for high-throughput screening, consult our internal guide on peptides for tissue repair research and automated dispensing.
Rigorous research outcomes require absolute chemical purity, lot-to-lot consistency, and freedom from biological contaminants. PX1 Research subjects every lot of CJC-1295 without DAC and Ipamorelin to rigorous third-party testing at an ISO 17025-accredited laboratory.
Chemical purity is established via Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum purity threshold of 99.0%. Mass identity is verified using Electrospray Ionization Mass Spectrometry (ESI-MS) or LC-MS/MS to confirm the exact molecular weight and sequence integrity against theoretical benchmarks.
In addition to structural verification, all lots undergo Chromogenic Limulus Amebocyte Lysate (LAL) testing to quantify bacterial endotoxin levels. Endotoxin contamination can cause non-specific inflammation in cell culture models and systemic pyrogenic responses in animal models. PX1 Research maintains strict endotoxin limits (<0.5 EU/mg) across all batches, providing researchers with reliable, reproducible reagents. Complete batch-specific Certificates of Analysis (COAs) are accessible for every shipment.
PX1 Research serves as a trusted supply partner for university laboratories, biotechnology organizations, and independent scientific institutions across the United States. All products are manufactured in domestic, GMP-compliant facilities utilizing solid-phase peptide synthesis (SPPS) methodologies.
Orders placed before 3:00 PM EST ship same-day from our dual distribution hubs located in California and Arizona, minimizing transit times and cold-chain disruption risks. Institutional buyers seeking large-scale custom synthesis or bulk order allocations can explore our dedicated portal for bulk laboratory research accounts to obtain tailored quotes and lot-reservation services.
What is the primary operational difference between CJC-1295 without DAC and CJC-1295 with DAC?
CJC-1295 without DAC (Modified GRF 1-29) lacks the Drug Affinity Complex moiety, resulting in a half-life of ~30 minutes and inducing pulsatile GH release. CJC-1295 with DAC binds to serum albumin, extending its half-life to several days and producing continuous elevation of baseline GH and IGF-1.
Why are CJC-1295 without DAC and Ipamorelin combined in research studies?
Co-administration targets two distinct complementary pathways on anterior pituitary somatotrophs: the GHRH receptor (via CJC-1295) and the GHS-R1a ghrelin receptor (via Ipamorelin). This dual activation creates a synergistic amplification of pulsatile growth hormone secretion greater than either compound alone.
Does Ipamorelin increase cortisol or prolactin during preclinical trials?
No. Preclinical research demonstrates that Ipamorelin is highly selective for the GHS-R1a receptor and does not induce statistically significant elevations in ACTH, cortisol, or prolactin, unlike first-generation secretagogues such as GHRP-2 or GHRP-6.
What purity levels are required for CJC-1295 without DAC and Ipamorelin in laboratory settings?
PX1 Research mandates a minimum purity threshold of ≥99.0% as verified by RP-HPLC and mass spectrometry analysis. High purity ensures experimental reproducibility and eliminates interference from truncated peptide fragments.
How should reconstituted CJC-1295 without DAC and Ipamorelin solutions be stored?
Once reconstituted with bacteriostatic water or sterile saline, liquid solutions should be kept refrigerated at 2°C to 8°C and used within 14 to 28 days. Avoid repeated freeze-thaw cycles.
What analytical methods verify the molecular weight of these peptides?
Liquid Chromatography-Mass Spectrometry (LC-MS) or Matrix-Assisted Laser Desorption/Ionization (MALDI-TOF) mass spectrometry are used to confirm exact monoisotopic mass and amino acid sequence fidelity.
What are the standard endotoxin thresholds for PX1 Research peptides?
PX1 Research ensures all research peptides are endotoxin-tested via the LAL assay with thresholds maintained below <0.5 EU/mg to prevent non-specific cellular or pyrogenic responses in experimental designs.
Can CJC-1295 without DAC and Ipamorelin be reconstituted in the same vial for assay prep?
Yes, in preclinical laboratory protocols where dual administration is specified, both peptides can be reconstituted in the same aqueous diluent without chemical cross-reactivity, provided proper aseptic techniques are maintained.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.